Regulatory approval

Published by the Health Canada. Approved

LYNPARZA is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. BRCA mutation must be confirmed before LYNPARZA treatment is initiated.

This is written in the approval document.

Citation

AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080849.PDF. Published June 2025. Accessed April 2026.

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations Biomarkers Cancer types Therapies
HC (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone
HC (1) BRCA1 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone
HC (1) BRCA2 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone
HC (1) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone
HC (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone
HC (1) BRCA1 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone
HC (1) BRCA2 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone
HC (1) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone